Abilify Does Not Typically Increase Diastolic Blood Pressure—It More Commonly Decreases It
Based on the FDA drug label and the highest quality clinical evidence, aripiprazole (Abilify) is more likely to cause orthostatic hypotension and blood pressure decreases rather than increases in diastolic BP. However, paradoxical hypertension has been reported in rare cases, likely through dopaminergic effects on the renin-angiotensin-aldosterone system 1.
Primary Blood Pressure Effects
The predominant cardiovascular effect of aripiprazole is hypotension, not hypertension:
- FDA labeling explicitly warns about orthostatic hypotension due to alpha1-adrenergic receptor antagonism, which can enhance the effects of antihypertensive medications 1
- In a controlled pharmacokinetic study of 157 healthy volunteers, aripiprazole produced a mean decrease of 6.2 mmHg in diastolic blood pressure and 9.3 mmHg in systolic pressure 2
- The incidence of orthostatic hypotension in clinical trials was low (1% vs 0.3% placebo in adults), but the mechanism predisposes to BP lowering 1
Paradoxical Hypertension: Rare but Documented
While uncommon, case reports document aripiprazole-induced hypertension through a distinct mechanism:
- A 16-year-old developed hypertension with elevated aldosterone/plasma renin activity ratio, which normalized after discontinuing aripiprazole 3
- A 53-year-old woman developed BP of 210/110 mmHg approximately 40 days after starting aripiprazole; BP normalized to 120/80 mmHg within 15 days of discontinuation 4
- Another case reported asymptomatic acute hypertension that resolved after stopping aripiprazole 5
The proposed mechanism involves dopamine receptor antagonism affecting the renin-angiotensin-aldosterone system (D1, D3, D4 receptors) and sympathetic nervous system (D2, D5 receptors), leading to secondary hyperaldosteronism in susceptible individuals 3, 4.
Clinical Context from Guidelines
The 2017 ACC/AHA hypertension guidelines identify atypical antipsychotics as medications that may cause elevated BP, but specifically recommend aripiprazole as a preferred alternative to clozapine and olanzapine due to its lower risk of weight gain, diabetes, and dyslipidemia 6, 7, 8. This guideline positioning suggests aripiprazole's hypertensive effects are less concerning than other atypical antipsychotics.
Practical Clinical Approach
Monitor blood pressure in all patients starting aripiprazole, recognizing that:
- Most patients experience BP decreases or orthostatic hypotension (the typical effect)
- Use caution when combining with antihypertensive medications due to additive hypotensive effects 1
- Rare patients may develop hypertension, particularly if they develop symptoms like headache, tachycardia, or nausea 4
- If hypertension develops, consider checking aldosterone/renin ratio to identify secondary hyperaldosteronism 3
- Hypertension typically resolves within 2-3 weeks of discontinuation 3, 4
Key Pitfall to Avoid
Do not assume all antipsychotics cause hypertension uniformly. Aripiprazole's pharmacologic profile (partial D2 agonism, alpha1-antagonism) differs fundamentally from other atypicals, making hypotension the more common cardiovascular concern rather than hypertension.